How to Get Rapamycin (Sirolimus) in Arizona

Rapamycin's FDA-Approved and Off-Label Uses

Rapamycin (sirolimus) received FDA approval in 1999 as an immunosuppressant for preventing organ rejection after renal transplantation. The drug inhibits the mechanistic target of rapamycin (mTOR), a kinase that regulates cell growth, proliferation, and metabolism. That same mTOR pathway is central to aging biology, which is why sirolimus has attracted attention for off-label longevity applications.

The PEARL trial (Aging Cell, 2024; N=150) evaluated weekly low-dose rapamycin in healthy older adults over 48 weeks, providing one of the first placebo-controlled datasets on tolerability and immune outcomes in a non-transplant population. Earlier work by Mannick et al. (Science Translational Medicine, 2014) demonstrated that an mTOR inhibitor improved immune function in elderly subjects, measured by response to influenza vaccination. A 2019 follow-up by Mannick et al. confirmed that low-dose mTOR inhibition reduced infection rates in adults aged 65 and older.

None of this makes rapamycin an FDA-approved anti-aging drug. Prescribers in Arizona who write sirolimus for longevity do so off-label, which is legal and common across U.S. medicine but places the evidence-review burden on the clinician and the informed-consent burden on the patient.

Arizona Telehealth Rules for Sirolimus Prescribing

Arizona permits telehealth prescribing of prescription medications, including sirolimus. Good news for patients outside metro Phoenix or Tucson: you do not need an in-person visit to start rapamycin.

Under Arizona Revised Statutes § 36-3602, a telehealth provider may establish a provider-patient relationship through a real-time audio-visual encounter. The Arizona Medical Board requires that the prescribing physician hold an active Arizona license or be part of a telehealth platform registered to practice in the state. The Federation of State Medical Boards (FSMB) has documented rapid expansion of interstate telehealth compacts, and Arizona is a member of the Interstate Medical Licensure Compact, broadening the pool of physicians available to Arizona patients.

A typical telehealth workflow for rapamycin prescribing follows this pattern: initial consultation (20 to 40 minutes), review of baseline labs, informed consent discussion covering off-label status and known risks, then electronic prescribing to a pharmacy of the patient's choice. Follow-up visits are generally scheduled at 6 to 12 week intervals for the first year.

Who Can Prescribe Rapamycin in Arizona

Three categories of licensed providers can write a sirolimus prescription in Arizona. MDs and DOs have independent prescriptive authority. Nurse practitioners (NPs) gained full practice authority in Arizona in 2001, though prescribing controlled and non-controlled substances may involve a collaborative agreement depending on practice setting. Physician assistants (PAs) prescribe under a supervisory arrangement with a licensed physician.

For off-label prescribing, the relevant standard across all provider types is the same: the clinician must document a reasonable medical basis for the prescription, provide informed consent, and monitor for adverse effects. The American Medical Association's guidance on off-label prescribing supports physician autonomy in evidence-based off-label use when the prescriber determines the benefit-risk ratio is favorable for the individual patient.

Most Arizona patients seeking rapamycin for longevity work with MDs or DOs who specialize in preventive or age-management medicine. This is not a regulatory requirement but a practical one: these providers are more likely to be familiar with the dosing protocols and monitoring schedules specific to low-dose weekly rapamycin.

Required Labs Before Starting Rapamycin in Arizona

No Arizona-specific lab mandate exists for sirolimus, but standard clinical practice requires baseline bloodwork before initiation. Here is what most prescribers order.

Baseline panel (before first dose):

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (CMP), including liver enzymes (AST, ALT) and kidney function (creatinine, eGFR)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Fasting glucose and/or HbA1c
• Optional: fasting insulin, hsCRP, ApoB

Rapamycin can raise triglycerides and LDL cholesterol in a dose-dependent manner. A meta-analysis in Transplantation (2015) found that sirolimus-based regimens in transplant patients increased mean triglycerides by 44% compared to calcineurin inhibitor-based regimens. Weekly low-dose protocols used off-label produce a smaller lipid effect, but monitoring remains necessary.

Sirolimus also suppresses blood cell production at higher doses. The FDA label lists thrombocytopenia, anemia, and leukopenia as known adverse reactions. At the 5 to 6 mg weekly doses used off-label, these events are infrequent, but a CBC at baseline and at 6 to 8 weeks catches early signals.

Follow-up monitoring schedule (typical):

• CBC and CMP at 6 to 8 weeks after initiation
• Fasting lipid panel at 8 to 12 weeks
• Subsequent labs every 3 to 6 months during the first year, then every 6 to 12 months if stable

Most labs can be drawn at any Quest Diagnostics or Sonora Quest location across Arizona. Mobile phlebotomy services are also available in Maricopa and Pima counties for patients who prefer home draws.

503A Compounding Pharmacies in Arizona

Arizona licenses 503A compounding pharmacies through the Arizona State Board of Pharmacy. These pharmacies can compound sirolimus into custom dosage forms (such as specific-strength capsules for weekly dosing) when a prescriber writes a patient-specific prescription.

The distinction matters. Commercial sirolimus tablets from Pfizer (brand name Rapamune) and generic manufacturers come in 0.5 mg, 1 mg, and 2 mg strengths. A patient on a 5 mg weekly protocol would need to combine multiple tablets. A 503A pharmacy can compound a single 5 mg or 6 mg capsule, simplifying adherence.

Arizona-based 503A pharmacies can fill prescriptions for Arizona residents and, in most cases, ship within the state. Interstate shipping from a 503A pharmacy is governed by the pharmacy's state of licensure and federal regulations under the Drug Quality and Security Act (DQSA). Some 503A pharmacies hold non-resident pharmacy licenses in multiple states, expanding their shipping reach. Patients should confirm with the pharmacy directly whether they hold the necessary licenses for their shipping address.

Out-of-state 503A pharmacies that are licensed as non-resident pharmacies in Arizona can also ship compounded sirolimus to Arizona addresses. This broadens access significantly, particularly for patients in rural parts of the state who may not live near a local compounding pharmacy.

Cost of Rapamycin in Arizona Without Insurance

Off-label rapamycin for longevity is not covered by Arizona Medicaid (AHCCCS) and is rarely covered by commercial insurance plans for this indication. Expect to pay out of pocket.

Generic sirolimus tablets (commercial pharmacy):

• GoodRx-reported prices for generic sirolimus 1 mg tablets range from approximately $25 to $90 for a 30-tablet supply at major Arizona chains
• A 6 mg weekly dose using 1 mg tablets costs roughly $30 to $55 per month with discount coupons

503A compounded sirolimus capsules:

• Compounded weekly-dose capsules typically range from $50 to $120 per month, depending on the pharmacy and capsule strength
• Some compounding pharmacies offer 90-day supplies at a lower per-month cost

Telehealth consultation fees:

• Initial visits range from $150 to $350
• Follow-up visits range from $75 to $200
• Lab work adds $50 to $200 per panel, depending on whether it is ordered through the telehealth provider or independently

The National Academy for State Health Policy tracks state telehealth payment parity laws. Arizona requires private insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, but this parity does not extend the coverage itself to off-label indications that the plan excludes.

Prior Authorization for Sirolimus in Arizona

Prior authorization (PA) for sirolimus in Arizona applies primarily to insured patients seeking coverage for an on-label or arguable off-label indication. For the most common scenario among longevity patients (self-pay, no insurance claim), prior authorization is not relevant.

When PA is required, Arizona insurers typically request the following documentation per AACE guidelines for immunosuppressive management:

• Diagnosis code (ICD-10) justifying the prescription
• Clinical notes documenting the medical necessity
• Lab results supporting the treatment decision
• Documentation of any failed prior therapies (step therapy)
• Prescriber's credentials and NPI number

Arizona's prompt-pay statute (ARS § 20-461) requires insurers to process clean claims within 30 days. PA decisions must be rendered within defined timeframes set by the specific plan, typically 72 hours for non-urgent requests. If denied, patients have the right to appeal through the insurer's internal process and subsequently through the Arizona Department of Insurance and Financial Institutions.

For transplant patients on sirolimus who are moving to Arizona and need to continue therapy, PA is usually straightforward because the indication is FDA-approved. Bring your most recent transplant clinic notes, current medication list, and last trough level result.

Transferring a Rapamycin Prescription to Arizona

Patients relocating to Arizona or snowbirds splitting time between states can transfer an existing sirolimus prescription. Arizona accepts prescription transfers from all 50 states under the Arizona Board of Pharmacy's transfer regulations.

The process works in two steps. First, contact the receiving Arizona pharmacy and provide your current pharmacy's information. The Arizona pharmacist will initiate the transfer by calling the originating pharmacy. Second, the prescriber's information transfers with the prescription, but the receiving pharmacy may contact the prescriber to verify.

For controlled substance prescriptions, transfer rules are stricter, but sirolimus is not a controlled substance. It is a prescription-only medication with no DEA scheduling. Transfers are typically completed within 24 to 48 hours.

One caveat: a compounded prescription from a 503A pharmacy cannot always be "transferred" in the traditional sense, because compounded medications are patient-specific and pharmacy-specific. If you were receiving compounded sirolimus from an out-of-state 503A pharmacy, your new Arizona prescriber may need to write a new prescription directed to an Arizona-licensed compounding pharmacy. A 2023 review in the Journal of the American Pharmacists Association discusses the regulatory complexity of interstate compounding transfers.

Timeline from Consultation to First Dose

Speed varies by pathway. Here is a realistic breakdown.

Telehealth pathway:

• Lab draw: day 1
• Lab results returned: days 3 to 5
• Telehealth consultation and prescription: days 5 to 7
• Pharmacy fill and shipping: days 7 to 12
• Total: 7 to 14 business days

In-person pathway (metro Phoenix or Tucson):

• Lab draw and same-day consultation (if labs pre-ordered): day 1
• Pharmacy fill (local pickup): days 2 to 4
• Total: 2 to 5 business days

The faster in-person timeline requires that labs be ordered and completed before the appointment. Many age-management clinics in Scottsdale, Phoenix, and Tucson offer this streamlined approach. If labs reveal an abnormality that needs follow-up, expect a 1 to 2 week delay regardless of pathway.

Compounding pharmacies may require 3 to 7 business days to fill a new prescription, compared to 1 to 2 days at a retail pharmacy dispensing commercial tablets. Factor this into your timeline if you prefer compounded capsules.

Safety Monitoring and When to Stop

Rapamycin is not a supplement. It is an immunosuppressant with a well-characterized side effect profile documented across decades of transplant literature. The off-label longevity doses are lower, but they are not zero-risk.

Stop rapamycin and contact your prescriber if you develop mouth ulcers that do not resolve within 7 days, persistent diarrhea, unexplained bruising or bleeding, recurrent infections, or significant edema. Oral mucositis is the most commonly reported side effect in low-dose rapamycin studies, affecting roughly 20 to 30% of participants in some trials. It is typically self-limiting and resolves with dose reduction or a brief drug holiday.

The Kaeberlein Lab's Dog Aging Project provided early mammalian data showing improved cardiac function in companion dogs receiving intermittent rapamycin, but canine and human pharmacokinetics differ. Extrapolating dog data to human dosing is done cautiously.

Your prescriber should reassess the benefit-risk ratio at each follow-up visit. If you are undergoing elective surgery, most clinicians recommend pausing rapamycin 1 to 2 weeks before the procedure given its effects on wound healing and immune function.